Prolonged infusions of β-Lactam antibiotics: Implication for antimicrobial stewardship

Pharmacotherapy

Volumn 32, Issue 8, 2012, Pages 707-721

  George, Jomy M ^a   Towne, Trent G ^b   Rodvold, Keith A ^c  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b MANCHESTER UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Dose optimization; Pharmacokinetic pharmacodynamics antimicrobial stewardship; Prolonged infusions

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CILASTATIN; CILASTATIN PLUS IMIPENEM; DORIPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ANTIMICROBIAL STEWARDSHIP; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG UTILIZATION; GRAM NEGATIVE INFECTION; HEALTH CARE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PYELONEPHRITIS; REVIEW; STRATEGIC PLANNING; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; ECONOMICS, PHARMACEUTICAL; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; TREATMENT OUTCOME;

EID: 84864590999     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01157.x     Document Type: Review

References (62)

1. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77.
2. Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010;32 (4):766-79.
3. Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospitalacquired pneumonia. Clin Ther 2009;31(11):2765-78.
4. Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother 2011;66(2):343-9.
5. Roberts JA, Kwa A, Montakantikul P, Gomersall C, Kuti JL, Nicolau DP. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: The PASSPORT Program-Asia Pacific Region. Int J Antimicrob Agents 2011;37(3):225-9.
6. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005;49(9):3944-7.
7. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009;64(1):142-50.
8. Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother 2009;43 (11):1747-54.
9. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: Prolonged or continuous infusion? Pharmacotherapy 2007;27(11):1490-7.
10. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44(3):357-63.
11. Patel GW, Patel N, Lat A, et al. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis 2009;64(2):236-40.
12. Yost RJ, Cappelletty DM, the RECEIPT Study Group. The retrospective cohort of extended infusion pipercillin-tazobactam (RECEIPT) study: A multicenter study. Pharmacotherapy 2011;31(8):767-75.
13. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
14. Petrosillo N, Drapeau CM, Agrafiotis M, Falagas ME. Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care. Minerva Anestesiol 2010;76 (7):509-24.
15. Roberts JA, Lipman J. Antibacterial dosing in intensive care: Pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006;45(8):755-73.
16. Nicolau DP. Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care 2008;12(Suppl 4):S2.
17. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: Implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008;46(6):862-7.
18. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999;43:2559-61.
19. Bhat SV, Peleg AY, Lodise TP Jr, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms. Antimicrob Agents Chemother 2007;51:4390-5.
20. Lee LS, Kinzig-Schippers M, Nafziger AN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 2010;68(3):251.
21. Nandy P, Samtani MN, Lin R. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother 2010;54(6):2354-9.
22. Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000;22(1):66-75.
23. Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol 2009;49(7):798-806.
24. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 2003;23(3):291-5.
25. Lodise TP Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004;48(12):4718-24.
26. Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: Use of population pharmacokinetic modeling and Monte Carlo simulation. Diagn Microbiol Infect Dis 2008;62(3):292-7.
27. Tsumura R, Ikawa K, Morikawa N, et al. The pharmacokinetics and pharmacodynamics of meropenem in cerebrospinal fluid of neurosurgical patients. J Chemother 2008;20(5):615-21.
28. Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 2003;31(8):2102-6.
29. Boselli E, Breilh D, Saux MC, Gordien JB, Allaouchiche, B. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Int Care Med 2006;32:2059-62.
30. Lodise TP, Sorgel F, Mason B, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid of patients with ventilator associated pneumonia. Antimicrob Agents Chemother 2011;4:1606-10.
31. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002-2006 OPTAMA programs for US hospitals: Focus on gramnegative resistance. Ann Pharmacother 2009;43(2):220-7.
32. Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 2010;54 (1):460-5.
33. Cheatham SC, Shea KM, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2011;37(1):46-50.
34. Nicasio AM, Ariano RE, Zelenitsky SA, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009;53(4):1476-81.
35. Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamicbased clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010;25 (1):69-77.
36. Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Int J Antimicrob Agents 2006;28(5):433-8.
37. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006;46(10):1171-8.
38. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator- associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005;49(4):1337-9.
39. Jaruratanasirikul S, Sudsai T. Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion. J Antimicrob Chemother 2009;63(3):560-3.
40. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008;36 (4):1089-96.
41. Réa-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: A randomized, open-label, multicenter study. Curr Med Res Opin 2008;24:2113-6.
42. Ikawa K, Morikawa N, Uehara S, et al. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents 2009;33(3):276-9.
43. Samtani MN, Flamm R, Kaniga K, Nandy P. Pharmacokineticpharmacodynamic- model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother 2010;54 (6):2360-4.
44. Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. Pharmacokinetic- pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009;63(4):409-14.
45. Keel RA, Sutherland CA, Crandon JL, Nicolau DP. Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents 2011;37(2):184-5.
46. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care unit). Antimicrob Agents Chemother 2002;46:2327-32.
47. Jaruratanasirikul S, Raungsri N, Punyo J, Sriwiriyajan S. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion. J Antimicrob Chemother 2005;56(6):1163-5.
48. The Henry J. Kaiser Family Foundation. United States: Hospital Adjusted Expenses per Inpatient Day, 2008. Available from http://www.statehealthfacts. org/profileind.jsp?ind=273&cat=5&rgn=1. Accessed March 31, 2011.
49. Xamplas RC, Itokazu GS, Glowacki RC, et al. Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital. Am J Health-Syst Pharm 2010;67:622-8.
50. Heinrich LS, Tokumaru, Clark NM, et al. Development and implementation of a pipiercillin/tazobactam extended infusion guideline. J Pharm Pract 2011;00:1-6.
51. Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy 2010;30(5):453-62.
52. Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2009;33(3):290-1.
53. Merchant S, Gast C, Nathwani D, et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008;30(4):717-33.
54. Kollef M, Nathwani D, Merchant S, et al. Medical resource utilization among patients with ventilator-assocaited pneumonia: Pooled analysis of randomized studies of doripenem versus comparators. Crit Care 2010;14:R84.
55. Zillerberg MD, Mody SH, Chen J, Shorr AF. Cost-effectiveness model of empiric doripenem compared with imipenemcilastatin in ventilator-associated pneumonia. Surg Infect (Larchmt) 2010;11(5):409-17.
56. Kongnakorn T, Mwamburi M, Merchant S, et al. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: Discrete event simulation. Curr Med Res Opin 2010;26(1):17-24.
57. Joseph JM, Rodvold KA. National surveys of prolonged and continuous infusions of B-lactams [Abstract]. Presented at: Infectious Diseases Society of America (IDSA) 2007 Meeting.
58. Psathas PA, Kuzmission A, Ikeda K, Yasuo S. Stability of doripenem in vitro in representative infusion solutions and infusion bags. Clin Ther 2008;30(11):2075-87.
59. Crandon JL, Sutherland C, Nicolau DP. Stability of doripenem in polyvinyl chloride bags and elastomeric pumps. Am J Health Syst Pharm 2010;67(18):1539-44.
60. Brammer MK, Chan P, Heatherly K, et al. Compatibility of doripenem with other drugs during simulated Y-site administration. Am J Health Syst Pharm 2008;65(13):1261-5.
61. Nolin TD, Lambert DA, Owens RC Jr. Stability of cefepime and metronidazole prepared for simplified administration as a single product. Diagn Microbiol Infect Dis 2006;56(2):179-84.
62. Baririan N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003;51(3):651-8.